Interferon alpha, Human Sampler (IFNa1) BioAssay(TM) Kit

Size: 12x20KU\n\nInterferons (IFNs) appear early after viral infection locally and systematically to limit spread of viral infection. They also affect cell differentiation, growth, surface antigen expression and immunoregulation. There are three naturally occurring interferons: alpha, beta and gamma. Interferon alpha (IFN-alpha, IFNa) is also known as leukocyte interferon. B-lymphocytes are the predominant cellular producers of INF-alpha. IFN-alpha is derived from lymphoblastic tissue. IFN-alpha comprises a family of related, homologous proteins, each exhibiting a unique activity profile. The activities of the different IFN-alpha species on viruses can vary twenty fold or more. INF-alpha has a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin. Recombinant IFN-alphas from both natural and synthetic genes bind to a common cell surface receptor and induce anti-viral activity in a variety of cell lines. When binding to discrete cell surface receptors on target cells, IFN-alpha induces rapid changes in Jak/Stat phosphorylation, which intiates the Jak/Stat signaling pathway. IFN-alpha signaling also involves production of DAG without an increased intracellular free calcium concentration and the subsequent activation of calcium-independent isoforms of PKC (beta and epsilon). All IFN-alpha signaling pathways lead to final alterations of gene expression, which mediate their pleiotropic biologic activities. IFN-alpha remains the most frequently used IFN for both research and clinical applications. It was first approved for combating malignancies. Anti-viral applications such as chronic Hepatitis B and C now make up the bulk of IFN sales. Different countries throughout the world have approved Hu-IFNa for different applications include: Chronic Hepatitis B, Chronic Hepatitis C, Hairy Cell Leukemia, Kaposi's Sarcoma (AIDS-related), Cutaneous T-cell Leukemia, Chronic Myeloid Leukemia, Renal Cell Carcinoma, Non-Hodgkin's Lymphoma, Adjuvant Therapy for Malignant Melanoma, Bladder Cell Carcinoma, Colon Carcinoma, Laryngeal Papillomatosis, Cervical Dysplasia, Condylomata Acuminata (Venereal Warts), Multiple Myeloma. \n\nBy testing and selecting specific alpha interferons to meet your research needs, you may benefit from improved effectiveness and reduced the quantity of cytokine required, thereby reducing experimental costs.\n\nKit Components (20,Ku):\nI7661-74B1 Alpha A \nI7661-74B2 Alpha B2\nI7661-74B3 Alpha C\nI7661-74B4 Alpha D\nI7661-74B5 Alpha F\nI7661-74B6 Alpha G\nI7661-74B7 Alpha H2\nI7661-74B8 Alpha I\nI7661-74B9 Alpha J1\nI7661-74B10 Alpha K\nI7661-74B11 Alpha 4b\nI7661-74B12 Alpha WA\n\nStorage and Stability:\nAliquot to avoid repeated freezing and thawing and freeze at -70 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

I7661-74

Size

12Vials

Form

Supplied as a liquid in PBS, pH 7.2, 0.1% BSA.

Purity

(same/more than)95%

References

1. Rubinstein, S., Familletti, P.C., Pestka, S., Convenient Assay for Interferons, J. Virol. 37: 755-758 (1981). 2. Familletti, P.C., Rubinstein, S., Pestka, S., A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon, in Methods in Enzymology, Vol. 78 (S. Pestka, ed.), Academic Press, New York, 387-394 (1981). 3. Pestka, S., Interferon Standards and General Abbreviations, in Methods in Enzymology (S. Pestka, ed.), Academic Press, New York 119: 14-23 (1986